531 results on '"Girard, N."'
Search Results
2. Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics project
3. Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort
4. Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R
5. Palliative care integration and end-of-life care intensity for patients with NSCLC
6. Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy
7. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
8. Les tumeurs thymiques: Thymic tumors
9. Impact of ERAS in breast reconstruction with a latissimus dorsi flap, compared to conventional management
10. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
11. A General Method For The Diagnosis Of Wind Turbine Systematic Yaw Error Based Solely On SCADA Data
12. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
13. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
14. Les tumeurs thymiques : principes de prise en charge
15. Caractéristiques cliniques et séquences thérapeutiques des patients atteints de cancer bronchique non à petites cellules (CBNPC) métastatique avec mutation KRAS G12C traités par sotorasib dans l’ATUc
16. Caractéristiques et prise en charge des patients porteurs de mutations complexes de l’EGFR dans les cancers bronchiques non à petites cellules : étude multicentrique rétrospective
17. Traitement des cancers bronchiques à petites cellules (CBPC) : intérêt des études en vie réelle. À propos de 2 études de l’IFCT : IFCT-1905 Clinatezo et IFCT-2105 Lurbiclin
18. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC
19. Évolution de l’incidence des métastases osseuses et de leur traitement par anti-résorbeurs en France entre 2009 et 2018 : étude OPTIMOS
20. 70P LIST (Lung Initiative on Sequence Therapy): A real-world study of nivolumab for advanced NSCLC in France - First effectiveness, safety, and IO-rechallenge results
21. MA08.04 Assessment of the Quality of the Surgical Procedure and the Operative Report Based on Nationwide French Registry: A RYTHMIC study
22. OA17.03 Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC (PACIFIC-R)
23. P2.09-29 Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)
24. MA12.03 New Data from the LungNENomics Project Provide Insights on the Supra-Carcinoid Emerging Variant of Lung Neuroendocrine Tumors
25. P1.28-09 Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel
26. VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
27. P2.16-06 A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC
28. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
29. Les tumeurs thymiques
30. Les tumeurs thymiques
31. Néoplasies neuro-endocrines broncho-pulmonaires primitives : tumeurs carcinoïdes et carcinomes neuro-endocrines à grandes cellules
32. P15 Indirect Treatment Comparisons of Time-to-Event Outcomes with Mis-Matched "Time Zero": Methodology and Application in Resectable Non-Small Cell Lung Cancer
33. Comment je fais… un lambeau musculaire de gracilis après une chirurgie d’exérèse vulvo-vaginale
34. VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
35. 84O Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816
36. 190P EORTC-SPECTA Arcagen project: Results of the prospective rare thoracic tumors cohort
37. 27P Amivantamab versus alternative real-world anti-cancer therapies in patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations in the US and Europe
38. Cáncer de endometrio: diagnóstico, estudio preterapéutico, tratamiento y seguimiento
39. Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer
40. 121P Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
41. Premières données de vraie vie des patients (pts) atteints d’un cancer bronchique non à petites cellules métastatique (CBNPCm) muté KRAS au sein du programme français d’autorisation temporaire d’utilisation (ATU) : caractéristiques cliniques de 679 pts à l’initiation du traitement
42. Nivolumab (NIVO) + doublet de chimiothérapie à base de sels de platine (chimio) versus chimio, en traitement néoadjuvant du cancer bronchique non à petites cellules (CBNPC) résécable (IB-IIIA) : corrélation entre survie sans évènement (EFS) et régression pathologique dans l’étude CheckMate 816
43. Placenta‐derived mesenchymal stromal cells as a treatment for refractory chronic gingivostomatitis in cats: eight cases (2018)
44. 75P Effectiveness and safety data from IMreal cohort 1: Patients (pts) with urothelial cancer (UC) receiving atezolizumab after platinum-containing chemotherapy (plt chemo) under real-world conditions
45. 58O Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable stage III non-small cell lung cancer (NSCLC): Interim analysis from the PACIFIC-R study
46. CO73 Amivantamab Versus Real-World Clinical Practice in Europe and the US for Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
47. 398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
48. Comment effectuer des comparaisons indirectes ajustées par appariement (MAIC) avec imputations multiples des données manquantes et dans un contexte de faibles échantillons ? Une méthodologie illustrée dans le cancer du poumon à partir d'essais cliniques agrégés et de la cohorte nationale ESME-AMLC
49. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
50. P4.07D.03 Phase 2 Peri-Operative Study of Fianlimab+Cemiplimab+Chemotherapy vs Cemiplimab+Chemotherapy in Resectable Early-Stage NSCLC.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.